2nd Annual Companion Diagnostics & Biomarkers 2019

Co-located with the Biobanking Event

14 - 15 February | Porto, Portugal

* * * InterContinental Porto - Palácio das Cardosas * * *
KEY PRACTICAL LEARNING POINTS

- Learn the recent advances and future perspectives in Companion Diagnostics & Biomarkers
- Understand the key aspects & challenges of Clinical Biomarker development & qualification Solutions for clinical development of precision therapies
- Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology
- Latest US and EU CDx regulation and guidance
- Regulatory landscapes for biomarkers and diagnostic tests
- Main barriers to progression of precision medicine in drug development
- The Role of In Vitro Diagnostics in Successful Precision Medicine Market Access
- Options for biomarker based patient stratification in NON-ONCOLOGY clinical development
- Key trends in targeted and immuno-oncology companion diagnostics
- Understand how better pharma/payer communications will be essential as more biological drugs with CDx hit the market.
- Strategic Partnerships for CDx – Challenges and Opportunities
The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.

Companion Diagnostics market is growing due to continuous advancement in medical technology both for the diagnosis and the treatment of patients. Rise in the prevalence of diseases like cancer & HIV is fueling to the growth of companion diagnostics as it assist in determining the patient specific dose and drugs.

The 2nd Annual Companion Diagnostics & Biomarkers 2019 will provide valued information about new IVD regulations, Dx reimbursement strategy, market access strategy to ensure successful commercialization with pharma & biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.
WHO SHOULD ATTEND
Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

- Companion Diagnostics
- Molecular Diagnostics
- Personalized Healthcare
- Clinical Development
- Regulatory Affairs
- Molecular Diagnostics
- Biomarkers
- Medical Sciences
- Experimental Medicine
- Translational Medicine
- Immunology
- Genomics
- Insurers
- Patient Advocates
- Payers
- Market Access
- Commercialization
- Oncology
- Non-oncology
- Rare Diseases
- Drug Development
- Research
SPEAKERS LIST

JOHN QUACKENBUSH
Chair of the Department of Biostatistics at the Harvard School of Public Health
US

RON VAN SCHAIK
Professor Pharmacogenetics Erasmus MC
NL

STEFAN KOSTENSE
Director, Biomarkers, Janssen (Johnson & Johnson)
NL

JANE WILKINSON
Senior Director, Genomics Platform Project & Alliance Management at Broad Institute
US

MARTINA KAUFMANN
Managing Director at Martina Kaufmann Strategic Consulting
DE

JAMES GODSEY
Vice President, R&D, Clinical Sequencing Division at Thermo Fisher Scientific
US

JOANNE HACKETT
Chief Commercial Officer at Genomics England
UK

DOLORES CAHILL
Professor of Translational Science, UCD School of Medicine, University College Dublin
IE
Over 20+ presentations and case studies focused on the key issues in Companion Diagnostics & Biomarkers. Join us at the Companion Diagnostics & Biomarkers 2019 in Porto.
Thursday, February 14, 2019

07:30  Registration and Welcome Coffee

08:30  Opening Ceremony by Chairperson Dr. Martina Kaufmann

TRENDS FOR COMPANION DIAGNOSTICS

08:35  Developing Biomarkers predicting the risk of onset of disease, for the purpose of developing treatments for disease prevention and interception
By Stefan Kostense - Director, Biomarkers at Janssen Prevention Center

09:10  Speed Networking

09:30  Democratization and Globalization of Next Generation Sequencing for Companion Diagnostics
By Jim Godsey - Vice President, Research and Development, Clinical Sequencing Division (CSD) at Thermo Fisher Scientific

10:00  Leveraging RWE to bring value to payers in personalized medicine
By Alexander Bastian - Vice President, Market Access & Pricing at Galapagos
- Overview of payer value drivers associated with personalized medicine
- Common gaps in the patient journey and payer submissions for personalized medicines
- RWE approaches to filling data gaps
- Potential challenges in RWE for personalized medicines

10:30  Morning Coffee and Networking Break

11:00  Development and Commercialization of CDx in the Era of Precision Medicine
By Steven M. Anderson - Chief Scientific Officer at Covance, Sr VP LabCorp

GLOBAL PERSPECTIVE OF CDX REGULATION

11:30  Scientific-Regulatory Challenges for Co-Development of Drug and Companion Diagnostics in Europe
By Jörg Engelbergs - Scientific-Regulatory Expert, Paul-Ehrlich-Institut
- Overview of current CDx regulatory requirements in the EU
- Challenges and requirements for analytical assay validation during clinical development
- Considerations on complex (multimarker) assays
- Ensuring diagnostic assay quality during clinical drug-Dx co-development and clinical routine

12:00  Panel Discussion: Regulation of CDx in the EU
Moderated by Charlotte Ryckman - Lawyer at Covington & Burling
- EU IVD Regulation: scope, timelines, and notified body challenges ahead
- IVD Regulation and CDx: challenges for co-development; interactions between EMA and NBs; implementation in clinical trials
Panelists: Jörg Engelbergs - Scientific-Regulatory Expert, Paul-Ehrlich-Institut | Andreas Stange - Vice President at TÜV SÜD | Martina Kaufmann - Managing Director at Martina Kaufmann Strategic Consulting

13:00  Business Lunch
### DEVELOPMENT AND COMMERCIALIZATION OF CDX

**14:00 Development and Commercialization of Biomarker Assays for Therapeutic and Diagnostic Guidance in NSCLC**
*By Gary Pestano - Vice President, Development and Operations at Biodesix, Inc.*
- Biomarker assay development and validation in a CAP/CLIA/NYS CLEP – approved Laboratory
- Strategies for successful reimbursement and commercialization of biomarker assays in a centralized Clinical Laboratory

**14:30 Mapping cancer risk SNPs to eQTL networks**
*By John Quackenbush - Chair of the Department of Biostatistics at Harvard T.H. Chan School of Public Health*
- Biomarkers tend to emphasize individual genes, but genes do not act alone
- Instead, genes and genetic variants act as elements of complex interacting networks
- These networks and their properties can be used to inform our understanding of disease and to develop pre...

### LIQUID BIOPSIIES IN PRECISION MEDICINE

**15:00 Liquid biopsy- the future of cancer diagnosis and precision medicine**
*By Yong Jie Lu - Professor in Molecular Oncology, Queen Mary University of London*

**15:30 Afternoon Tea and Networking Break**

**16:00 Accelerating Development of Liquid Biopsy technology**
*By Lauren C. Leiman - Executive Director at BloodPAC*
- Establishing standards to accelerate development and approval of liquid biopsy technology
- White House Cancer Moonshot overview
- Creation of the BloodPAC Consortium and BloodPAC Data Commons as a commitment to the Cancer Moonshot and then as an independent entity
- BloodPAC Consortium process and project strategies
- Technology development process
- Creation of standards for pre-analytics, analytics, clinical validation
- Example past projects, current projects and future projects

### ROLE OF IMAGING IN THE ERA OF PRECISION MEDICINE

**16:30 Image-based CDx solutions**
*By Carla Leibowitz - Global head of healthcare partnerships at NVIDIA*

**17:00 Nuclear Medicine Imaging for Diagnosing Cancer**
*By Joana Brilhante - Head of Clinical Development at AIPES*
- What is nuclear medicine?
- For what is nuclear medicine used?
- What are the benefits for the doctor and for the patient?

**17:30 Chairman’s Closing Remarks**

**20:00 Gala Dinner**
Friday, February 15, 2019

08:00  Registration and Welcome Coffee
08:25  Opening Address by Dr. Jane Wilkinson

**INNOVATION IN GENOMIC MEDICINE IMPLEMENTATION**

08:30  Bringing cancer genomics into the clinic  
*By Joanne M. Hackett - Chief Commercial Officer at Genomics England*
- Genomics England is harnessing the power of the NHS to bring cancer genomics into the clinic
- Addressing barriers to clinical adoption such as the practical problems of pharmaco-economics
- Incorporating prior biological knowledge

09:00  Genomics challenges from a single sample to large clinical studies  
*By Jane Wilkinson - Senior Director, Broad Genomics Alliance & Project Management at Broad Institute of MIT and Harvard*
- Highlighting our process development to tackle difficult samples
- Reviewing our capabilities in managing high volumes of data generation and analysis
- Collaborating to develop new genomics applications
- Globally collaborating with researchers to drive them closer to the cure

09:30  Pharmacogenetics in clinical practice: do YOU have your DNA passport?  
*By Ron van Schaik - Professor Pharmacogenetics at Erasmus MC*
- Adverse drug reactions are responsible for 5-7% of hospitalizations
- 80% of all drugs are being metabolized by cytochrome P450 enzymes in the liver, yet, not everybody has the full potential of all these enzymes.
- By analyzing genetic variants in CYP450 enzymes, one can tailor drug therapy
- This is now operational in the Netherlands for over 15 years, where you can visit your local pharmacists with your DNA information for personalized drug therapy.

**STRATEGIES FOR CDX**

10:00  Should every cancer patient be sequenced?  
*By Christophe Le Tourneau - Senior medical oncologist at the Institut Curie*
- Tumor sequencing has open the door of precision medicine in oncology
- Histology-agnostic treatment of cancer is now a reality with two anti cancer drugs approved across histologies based on specific molecular alterations
- While tumor sequencing should be performed in all patients with recurrent cancer, this should not be used to give off-label drugs

10:30  Morning Coffee and Networking Break

11:00  A global perspective on BRCA gene testing: a new paradigm for molecular testing in breast and ovarian cancer  
*By Simon Patton - Director at European Molecular Genetics Quality Network (EMQN)*
11:30 Exosome-derived epigenetic biomarkers for saliva diagnostics
By Christa Noehammer - Senior Scientist bei AIT Austrian Institute of Technology

12:00 From Eligibility to CDx: Developing and Implementing Effective Biomarker Strategies for Immuno-Oncology Trials
By Alexandre Passioukov - Vice President Translational Medicine at Pierre Fabre
- Deep understanding of the tumor and the anti-tumor immune response
- Biomarker strategies and a comprehensive toolkit for biomarker testing

12:30 Capabilities in rapid lateral flow technology for companion and complementary diagnostics – Seralite-FLC case study
By Lisa Mansell - Business Development Manager at Abingdon Health

13:00 Business Lunch

14:00 The discovery and description PDE4D7 as a new prognostic biomarker for advancing prostate cancer
By David J P Henderson - Senior Biologist at Mironid
- The rationale behind the project and the project timelines
- A description of the initial characterization of the biomarker, and subsequent validation and follow-up studies
- Its current status: anticipated launch by MDxHealth as ‘InformMDxTM’ in 2019

14:30 Recent Developments in Companion Diagnostics in Auto-immune Disease and Immunooncology
By Dolores J. Cahill - UCD School of Medicine, University College Dublin
- Overview of the technologies, tests, costs, health economics, benefits and adverse event profiling

15:00 The Digital and In Silico Therapeutics Revolution
By Carolina Garcia Rizo - Chief Business Officer at Just Biotherapeutics
- Digital and in silico therapeutics
- Digital and in silico diagnostics

15:30 Genetic biomarker-based patient stratification in non-oncology
By Ana Alfirevic - Reader in Pharmacology at University of Liverpool
- Clinical development of genetic biomarker panels
- Validation of genetic biomarker panels
- Implementation of genetic testing into clinical practice
- Barriers and facilitators to implementing clinical care pathways

16:00 Chairman’s Closing Remarks
Dr. Pestano leads the Development and Operations departments at Biodesix, a molecular diagnostics company. He is the New York State Clinical Laboratory Evaluation Program (CLEP) Laboratory Director in Boulder, CO of the company’s CLIA, CAP, CLEP, and ISO 13485-certified laboratory. His experiences in the development of high complexity molecular diagnostics tests includes molecular and proteomic approaches.

Joana has a background in Nuclear Medicine imaging and a Masters of Science in Clinical Research. She worked in the clinic environment and has directed her career towards industry, working in the management of imaging operation in multicenter clinical trials. She has also been involved in the development of diagnostic and therapy novel PET tracers in EU and US markets.

Lauren C. Leiman is currently the Executive Director of the Blood Profiling Atlas in Cancer (BloodPAC), a consortium focused on creating an open database for liquid biopsies to accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit. Prior to running BloodPAC, she was the Senior Director of External Partnerships at White House Cancer Moonshot Task Force during the Obama Administration.

Christa Noehammer currently works as Senior Scientist at the Austrian Institute of Technology where she has been heading the Molecular Medicine research unit for several years. Holding a master degree in Microbiology and a PhD in Biochemistry she has been working in the microarray field since 1999 being involved in the design, production and data analysis of various microarray types thereby mainly focusing on minimally invasive biomarker discovery for cancer diagnostics.

Alex is the Head of Global Value, Access, & Pricing within Global Product Strategy at Incyte Corporation, a innovative biotechnology company that focuses on oncology development. He leads a function responsible for developing and implementing global pricing and reimbursement strategies, including health economics and outcomes research support for all pipeline assets at Incyte. Alex’s role is to determine how to develop, communicate, and capture value for new innovative drugs in markets across the globe.

Dr Lisa Mansell has 18 years of experience in the diagnostic industry including rapid lateral flow diagnostics, ELISA assays, and mass spectrometry methods. Lisa has a degree in Biomedical Science and a PhD in Forensic Toxicology. As Business Development Manager for Abingdon Health’s contract services business she is responsible for managing new lateral flow diagnostic development and manufacturing opportunities.

Lauren has 18 years of experience in the diagnostic industry including rapid lateral flow diagnostics, ELISA assays, and mass spectrometry methods. Lisa has a degree in Biomedical Science and a PhD in Forensic Toxicology. As Business Development Manager for Abingdon Health’s contract services business she is responsible for managing new lateral flow diagnostic development and manufacturing opportunities.

LISA MANSELL, UK
Business Development Manager at Abingdon Health

LAUREN LEIMAN, US
Executive Director at BloodPAC

JOANA BRILHANTE, PT
Head of Clinical Development at AIPES

GARY PESTANO, US
Vice President, Development and Operations at Biodesix, Inc.

CHRISTA NOEHAMMER, AT
Senior Scientist at the Austrian Institute of Technology

ALEXANDER BASTIAN, US
Vice President, Market Access & Pricing at Galapagos
Charlotte Ryckman is a senior associate in the life sciences practice of Covington & Burling, based in Brussels. Ms. Ryckman assists clients across a complex range of regulatory, legal and procedural matters. Her practice focuses on the European Union rules and on the laws in key EU Member States, including Belgium and The Netherlands.

Dr. Andreas F. Stange is a vice president for the Medical and Health Services group at TÜV SÜD Product Service. He serves as the global responsible for the In-vitro Diagnostic Devices business line. Dr. Stange joined TÜV SÜD in 2001 as medical device expert and had various positions since then in the group. Before taking the current position in March 2017, he was President & CEO of TÜV SÜD in Japan.

Prof. Dr Dolores Cahill has over 25 years expertise in high-throughput protein array, antibody array, proteomics technology development, automation and their biomedically applications, including in biomarker discovery, diagnostics and personalised medicine. She is Professor of Translational Science, School of Medicine and at the Conway Institute at the University College Dublin (UCD) (2005-present).

Ana’s research has been focused on molecular pharmacology and pharmacogenetics. She has been working on discovery and implementation of genetic factors predisposing to immune-mediated adverse drug reactions (ADRs). In cardiovascular pharmacology, her research aims at investigating genetic factors predisposing to statin-induced myopathy by utilizing next generation sequencing strategy.

Prof. Dr. Ron van Schaik (PhD, FACB) is a registered European Specialist Laboratory Medicine and a Full Professor of Pharmacogenetics. He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, and is Director of the International (IFCC) Expert-center for Pharmacogenetics. Main interest is the clinical implementation of pharmacogenetics and pharmacogenetics translational research.

Jane is a Senior Director at the Broad Institute where she leads the Broad Genomics Alliance Management team. In this role, Jane manages the platform’s external collaborations and alliances, overseeing the successful implementation and execution. She also works to ensure that the platform meets complex goals from a variety of scientific project types with specific deliverables and deadlines of partnerships, as well as serving as an advocate for those partnerships.

Stefan Kostense, PhD, Director, Biomarkers, Janssen (Johnson & Johnson) has set up the Clinical Immunology department of 35 FTE, and set up a GLP and GCLP compliant laboratory including LIMS, for the analysis of toxicity and clinical samples, supporting the development of antibody therapeutics and vaccines.

Steven Anderson is senior vice president and chief scientific officer for Covance Drug Development. He has worked for LabCorp for 30 years and has held a variety of positions, including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrative Oncology and Integrated Genetics, national director of research and development, and global head of LabCorp Clinical Trials.
John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health. John’s PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005.

Professor Joanne Hackett is the Chief Commercial Officer at Genomics England and lead member of the Business and Investment Committee. As CCO, Joanne is responsible for Genomics England’s industry engagement strategy by developing, managing and accelerating relationships with commercial organisations – creating opportunities for collaboration both nationally and globally. Joanne is a clinical academic with a formidable track record of entrepreneurial success, as she translates academic research into medical and commercial returns.

Mironid Ltd is an innovative drug discovery company focused on delivering new best-in-class therapeutics for kidney disease, inflammation and cancer. David is responsible for the efficient and effective delivery of lab based and collaborative research programs covering novel compound development, biomarker discovery and target validation. Prior to taking up this position with Mironid, David won a prestigious Innovation Fellowship at the Salk Institute for biological studies, San Diego, for his work in epigenetic dysregulation in precancerous disease.

Carolina is the Chief Business Officer of Just Biotherapeutics, an AI-driven platform that allows bringing biotherapeutics faster, with lower resources, yet highest quality to the market. Carolina has more than 15 years of strategy, business development, commercial and operational experience within the biopharmaceutical and medical device industries. Carolina was the Global Director, Business Development at Thermo Fisher Scientific, where she was responsible for developing strategic partnerships across the pharmaceutical and healthcare industries for the commercialization of oncology-based diagnostics and companion diagnostics.

Dr. Engelbergs is currently working for the Paul-Ehrlich-Institut in Langen, Germany, as regulatory-scientific expert and assessor (Quality / CMC and Non-Clinic) for biopharmaceuticals with focus on Biotechs (Monoclonal Antibodies) and further as expert for IVDs / biomarker based Companion Diagnostics (CDx) and stratified / personalized (Bio-) Medicines. He is involved in the European process of market authorization of biopharmaceuticals, comprising scientific assessments and national / EMA advices. Further activities are assessments of GCP conformity of clinical phase I-III trials, national and third-country (USA, East Asia) GMP inspections, and experimental research on biomarkers.

Alexandre Passioukov leads translational medicine efforts across oncology, CNS and dermatology therapeutic areas at Pierre-Fabre R&D. Previously, Dr. Passioukov was leading translational medicine programs at Roche (Switzerland) with a special focus on immune-oncology drugs. Prior to joining Roche, Alexandre served as Head of Translational Research at EORTC in Brussels, conducting structural translational medicine activities of European clinical research networks. Alexandre is MD with PhD in biology by Université Catholique de Louvain (UCL), where he was closely involved in the launch of 2 spin-off biotech companies: Coulter Pharma Belgium and Diatos.
Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at the Versailles-Saint-Quentin-en-Yvelines University. He is heading the Department of Drug Development and Innovation as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program.

**Christophe Le Tourneau, FR**
Senior Medical Oncologist & Professor of Medicine at Institut Curie & UVSQ

Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances for several products and a platform that combine cloud computing and artificial intelligence in the medical imaging space. In her role, Carla oversees corporate strategy and planning, business development, geographic expansion and investor relations. She has an MBA from the Stanford Graduate School of Business and engineering degrees from both MIT and Stanford.

**Carla Leibowitz, US**
Global head of healthcare partnerships at NVIDIA

Yong-Jie Lu is a professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London. He completed his medical training in 1989, MD in 1992 and PhD in 1995. He did his postdoctoral studies 1995 to 2001 at Cancer Genetics Laboratory, Institute of Cancer Research, London, where he was promoted to a permanent post, senior staff scientist. In 2003, he moved to his current institute to set up a male urological cancer genetic and biomarker study programme. His current research focus on circulating biomarker development, aiming to translate them into cancer diagnosis, prognosis and therapeutic stratification. He published >100 original research papers.

**Yong-Jie Lu, UK**
Professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London

Dr. Godsey has an extensive background (30+ years) in Technology Discovery, Product Development and general management in the infectious disease and cancer diagnostic industry. He joined Thermo Fisher Scientific in 2015 as the Clinical Sequencing Division was established. He is responsible for all Technology Development, Assay Development, Bioinformatics and Instrument Development related to Next Generation Sequencing at 7 sites located within the US, including the division’s CLIA laboratory. Dr. Godsey’s Team gained FDA and PMDA approval of the first multi-variant, multi-drug NGS CDx for NSCLC, the Oncomine Dx Target Test.

**James Godsey, US**
Vice President, R&D, Clinical Sequencing Division at Thermo Fisher Scientific

Simon Patton, PhD is currently Director of the European Molecular Genetics Quality Network (EMQN) - the global leader in the provision of External Quality Assessment (EQA) schemes to diagnostic laboratories in the fields of genetics and pathology. He trained at the University of Liverpool in marine biology, before doing his doctorate in Genetics at the University of Cambridge. He is currently at Manchester University NHS Foundation Trust. Simon’s work has focussed on global improvement in the standards and quality of diagnostic laboratory testing – a field that he has worked in since 1999 through his involvement with the EMQN.

**Simon Patton, UK**
Director at European Molecular Genetics Quality Network (EMQN)

Dr. Martina Kaufmann, Managing Director at Martina Kaufmann Strategic Consulting (www.mk-stracon.com) has 15+ years industry experience in the field of personalized medicine - from biomarker validation, companion diagnostcs development to implementation of such products in the market. She served in various roles of increasing responsibility in business and development functions in small biotech/diagnostic companies as well as in global pharmaceutical & diagnostics corporations (Hoffmann-La Roche AG, Novartis Pharma AG, Novartis Molecular Diagnostics), where she e.g. led the Herceptin® biomarker / companion diagnostics activities and did build up the oncology biomarker group in Basel, respectively.

**Martina Kaufmann, DE**
Managing Director at Martina Kaufmann Strategic Consulting
### Sponsors

<table>
<thead>
<tr>
<th>ABINGDON HEALTH</th>
<th>COVANCE SOLUTIONS MADE REAL</th>
<th>OPERON IMMUNO &amp; molecular diagnostics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>scailyte™</td>
</tr>
</tbody>
</table>

### Partners

<table>
<thead>
<tr>
<th>Pharma Technology Focus</th>
<th>BlueSEQ</th>
<th>Farmavita.Net</th>
<th>BENTHAM SCIENCE</th>
<th>medicina</th>
<th>Bio-S Partner</th>
<th>Biobanking.com</th>
<th>pharmapchorum</th>
<th>Gate2Biotech</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LABIOTECH.eu</th>
<th>Bio-Equip</th>
<th>TAP PORTUGAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ASSOC. GÊN. DE PORTO ENOTE</th>
<th></th>
<th></th>
</tr>
</thead>
</table>
VENUE
InterContinental Porto - Palácio das Cardosas

**Location**
The hotel stands prominently at the end of Porto’s main avenue, Avenida dos Aliados, and is hence in the most central part of the city. The São Bento train station is just 100 metres away and the iconic Clérigos Tower is a three-minute walk.

**Service & facilities**
Facilities include a delightfully fragranced wellness centre where a range of massages are offered (the candle wax massage is highly recommended), as well as facial treatments and waxing services. The centre also includes a decent-sized 24-hour gym and sauna, but no pool or steam room.

**Food & drink**
The hotel includes the classy Bar das Cardosas, which offers live music most nights of the week, and the Astória Restaurant, where we sampled a seasonal degustation with sommelier wine pairing.